- Home
- IMAB vs ALRN Comparison
IMAB vs ALRN Comparison
Compare IMAB & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ALRN
- Stock Information
- Founded
- IMAB 2014
- ALRN 2001
- Country
- IMAB United States
- ALRN United States
- Employees
- IMAB N/A
- ALRN 3
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ALRN Health Care
- Exchange
- IMAB Nasdaq
- ALRN Nasdaq
- Market Cap
- IMAB 83.8M
- ALRN 76.9M
- IPO Year
- IMAB 2020
- ALRN 2017
- Fundamental
- Price
- IMAB $1.39
- ALRN $3.46
- Analyst Decision
- IMAB Strong Buy
- ALRN Strong Buy
- Analyst Count
- IMAB 3
- ALRN 1
- Target Price
- IMAB $8.00
- ALRN $19.00
- AVG Volume (30 Days)
- IMAB 378.4K
- ALRN 105.2K
- Earning Date
- IMAB 08-28-2024
- ALRN 10-15-2024
- Dividend Yield
- IMAB N/A
- ALRN N/A
- EPS Growth
- IMAB N/A
- ALRN N/A
- EPS
- IMAB N/A
- ALRN N/A
- Revenue
- IMAB $3,492,091.00
- ALRN N/A
- Revenue This Year
- IMAB N/A
- ALRN N/A
- Revenue Next Year
- IMAB N/A
- ALRN N/A
- P/E Ratio
- IMAB N/A
- ALRN N/A
- Revenue Growth
- IMAB N/A
- ALRN N/A
- 52 Week Low
- IMAB $0.99
- ALRN $1.01
- 52 Week High
- IMAB $2.54
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- IMAB 63.28
- ALRN 58.19
- Support Level
- IMAB $1.02
- ALRN $3.30
- Resistance Level
- IMAB $1.50
- ALRN $3.63
- Average True Range (ATR)
- IMAB 0.10
- ALRN 0.35
- MACD
- IMAB 0.04
- ALRN -0.00
- Stochastic Oscillator
- IMAB 77.08
- ALRN 68.65
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.